These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8083716)

  • 1. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity.
    Stewart CF; Baker SD; Heideman RL; Jones D; Crom WR; Pratt CB
    J Clin Oncol; 1994 Sep; 12(9):1946-54. PubMed ID: 8083716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.
    Furman WL; Baker SD; Pratt CB; Rivera GK; Evans WE; Stewart CF
    J Clin Oncol; 1996 May; 14(5):1504-11. PubMed ID: 8622064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.
    Baker SD; Heideman RL; Crom WR; Kuttesch JF; Gajjar A; Stewart CF
    Cancer Chemother Pharmacol; 1996; 37(3):195-202. PubMed ID: 8529278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
    van Warmerdam LJ; Verweij J; Schellens JH; Rosing H; Davies BE; de Boer-Dennert M; Maes RA; Beijnen JH
    Cancer Chemother Pharmacol; 1995; 35(3):237-45. PubMed ID: 7805183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
    Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
    Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.
    Wall JG; Burris HA; Von Hoff DD; Rodriguez G; Kneuper-Hall R; Shaffer D; O'Rourke T; Brown T; Weiss G; Clark G
    Anticancer Drugs; 1992 Aug; 3(4):337-45. PubMed ID: 1330081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of topotecan.
    Herben VM; ten Bokkel Huinink WW; Beijnen JH
    Clin Pharmacokinet; 1996 Aug; 31(2):85-102. PubMed ID: 8853931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.
    Tubergen DG; Stewart CF; Pratt CB; Zamboni WC; Winick N; Santana VM; Dryer ZA; Kurtzberg J; Bell B; Grier H; Vietti TJ
    J Pediatr Hematol Oncol; 1996 Nov; 18(4):352-61. PubMed ID: 8888741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, pharmacokinetic and biological studies of topotecan.
    O'Dwyer PJ; LaCreta FP; Haas NB; Halbherr T; Frucht H; Goosenberg E; Yao KS
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S46-52. PubMed ID: 8070027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
    Burris HA; Awada A; Kuhn JG; Eckardt JR; Cobb PW; Rinaldi DA; Fields S; Smith L; Von Hoff DD
    Anticancer Drugs; 1994 Aug; 5(4):394-402. PubMed ID: 7949242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients.
    Takimoto CH; Dahut W; Marino MT; Nakashima H; Liang MD; Harold N; Lieberman R; Arbuck SG; Band RA; Chen AP; Hamilton JM; Cantilena LR; Allegra CJ; Grem JL
    J Clin Oncol; 1997 Apr; 15(4):1492-501. PubMed ID: 9193345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
    J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
    Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of the clinical pharmacology of topotecan.
    Dennis MJ; Beijnen JH; Grochow LB; van Warmerdam LJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-12-S5-18. PubMed ID: 9122737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
    Creemers GJ; Gerrits CJ; Eckardt JR; Schellens JH; Burris HA; Planting AS; Rodriguez GI; Loos WJ; Hudson I; Broom C; Verweij J; Von Hoff DD
    J Clin Oncol; 1997 Mar; 15(3):1087-93. PubMed ID: 9060549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacologic study of topotecan in patients with impaired renal function.
    O'Reilly S; Rowinsky EK; Slichenmyer W; Donehower RC; Forastiere AA; Ettinger DS; Chen TL; Sartorius S; Grochow LB
    J Clin Oncol; 1996 Dec; 14(12):3062-73. PubMed ID: 8955651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
    Zackrisson AL; Malmström H; Peterson C
    Eur J Clin Pharmacol; 2002 May; 58(2):103-8. PubMed ID: 12012141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.
    Grochow LB; Rowinsky EK; Johnson R; Ludeman S; Kaufmann SH; McCabe FL; Smith BR; Hurowitz L; DeLisa A; Donehower RC
    Drug Metab Dispos; 1992; 20(5):706-13. PubMed ID: 1358575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
    Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
    Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
    Eder JP; Supko JG; Lynch T; Bryant M; Vosburgh E; Shulman LN; Xu G; Kufe DW
    Clin Cancer Res; 1998 Feb; 4(2):317-24. PubMed ID: 9516917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.